TMS Therapy for Bipolar Disorder and Bipolar Depression

Adult seated in a psychiatric consultation room beside a brain model

TMS therapy for bipolar disorder means using transcranial magnetic stimulation to treat the depressive phase of bipolar I or bipolar II disorder, not mania. For most devices in the United States this is an off-label use, because the FDA clearance dates from 2008 and covers major depressive disorder. The research so far points to a modest but real antidepressant effect and a mood-switch rate no higher than with sham treatment, although the largest trials are still to come.

Is TMS Approved for Bipolar Disorder?

TMS received FDA clearance for major depressive disorder in 2008, and that remains the cleared indication for most TMS devices. Using it for bipolar depression is therefore off-label for most systems. A 2025 systematic review in Biological Psychiatry Global Open Science notes that rTMS has recently received FDA breakthrough status for bipolar depression, a designation meant to speed up development and review rather than a clearance for patients to use. Off-label does not mean unsupported, but it does affect insurance coverage, which is covered further down.

The Phase of Bipolar Disorder That Gets the Least Attention

When most people picture bipolar disorder, they think of the manic episodes - the sleepless energy, the impulsive decisions, the racing thoughts that feel electric before they turn catastrophic. But research consistently shows that people with bipolar disorder spend far more time in the depressive phase than in elevated mood states. A landmark longitudinal study by Judd and colleagues, published in Archives of General Psychiatry, found that patients with bipolar I disorder spent roughly 32 percent of tracked weeks experiencing depressive symptoms, compared to about 9 percent in manic or hypomanic symptoms. For bipolar II disorder, the imbalance is even more pronounced - depressive episodes dominate the illness course, with hypomania representing only a fraction of time ill.

Bipolar depression is not simply ordinary sadness with a clinical label. It brings a physical heaviness that makes getting out of bed feel genuinely impossible, alongside cognitive fog, profound fatigue, and a persistent hopelessness that can last for weeks or months at a stretch. Many people with bipolar disorder find that their depressive episodes persist despite thoughtful, evidence-based treatment. For these patients, transcranial magnetic stimulation (TMS) has become a part of the treatment picture worth understanding. This article explains the clinical challenge of bipolar depression, how TMS works, what the research shows (including where it is mixed), and what a course of treatment typically looks like in the Boca Raton area. For the general background, see the guide on what TMS therapy is and how it works.

Why Bipolar Depression Is Uniquely Difficult to Treat

Bipolar depression and major depressive disorder can look nearly identical from the outside. The withdrawn behavior, disrupted sleep, loss of motivation, and feelings of worthlessness overlap substantially between the two conditions. But they have different neurobiological underpinnings, and - critically - the treatment approaches that help unipolar MDD can actively harm people with bipolar disorder.

The most significant clinical concern is antidepressant-induced mood switching. When a person with bipolar disorder is prescribed a standard antidepressant - an SSRI, SNRI, or older tricyclic - there is a documented risk that the medication tips the mood too far in the opposite direction, triggering hypomania or full mania. Research has confirmed this is a real-world phenomenon affecting a meaningful subset of bipolar patients, with rates varying depending on the specific drug used, bipolar subtype, and whether a mood stabilizer is also prescribed. For bipolar I patients, the concern is particularly acute - a triggered manic episode can derail relationships, employment, finances, and physical safety.

The FDA-approved pharmacological treatments for bipolar depression include quetiapine (Seroquel), lurasidone (Latuda), and cariprazine (Vraylar) among atypical antipsychotics, as well as olanzapine-fluoxetine combination (Symbyax). Lithium and lamotrigine (Lamictal) are foundational mood stabilizers in bipolar management with strong evidence for reducing the depressive burden over time, though their specific FDA indications address different aspects of bipolar illness. These are legitimate and often effective tools - but they do not work for every patient, and tolerability is a persistent challenge.

Lithium requires regular blood level monitoring and carries risks to kidney and thyroid function over long-term use. Lamotrigine requires a cautious titration schedule to minimize a small but serious risk of severe skin reaction. Quetiapine causes sedation and weight gain in many patients. Lurasidone and cariprazine are better tolerated by some patients but still leave a meaningful portion with only partial relief. When a patient has tried several of these options without achieving full remission from the depressive phase - or when side effects have become untenable - something additional is needed. The broader picture of depression that has not responded to medication is covered in the guide to TMS for treatment-resistant depression.

How TMS Works and Why It Matters for Bipolar Depression

Transcranial magnetic stimulation delivers brief, focused magnetic pulses to specific areas of the brain through the scalp and skull. No surgery is involved, no anesthesia is required, and patients remain awake and alert throughout each session. The magnetic pulses, comparable in strength to those used in MRI machines, induce small electrical currents in targeted neurons. Over a course of treatment, this stimulation appears to shift the activity patterns in brain circuits that regulate mood - not by introducing a chemical into the bloodstream, but by directly modulating neural excitability in targeted regions.

The most commonly targeted area for depression is the left dorsolateral prefrontal cortex, or left DLPFC - a region consistently shown to be underactive in depressive states across both unipolar and bipolar depression. High-frequency repetitive TMS applied to this area has an activating, stimulating effect. Low-frequency TMS applied to the right DLPFC has the opposite effect - it is inhibitory - and is sometimes used when anxiety or agitation is prominent alongside the depressive episode, a presentation that is common in bipolar disorder.

A newer delivery method called theta burst stimulation, or TBS, has become widely available and validated. Intermittent TBS applied to the left DLPFC can deliver the same therapeutic effect in as little as three to six minutes per session, compared to twenty to forty minutes for older standard rTMS protocols. The 2025 review of bipolar depression found left DLPFC iTBS to be noninferior to high-frequency rTMS - meaning the faster protocol appears to work as well. This has made TMS considerably more practical for patients with professional obligations and family responsibilities.

From a bipolar-specific standpoint, TMS has two properties that make it particularly relevant. First, it is not a systemic treatment. The magnetic pulses act locally on targeted neural circuits and do not affect the body's metabolism or interact with the pharmacokinetics of any medication. Lithium blood levels, valproate concentrations, lamotrigine levels, and antipsychotic plasma concentrations are all unaffected by TMS. This makes TMS genuinely additive when used alongside an existing medication regimen rather than disrupting it. Second - and critically important for bipolar patients - TMS does not appear to trigger the manic mood switches that have made antidepressant prescribing so complicated in this population.

Does TMS Work for Bipolar Depression? What the Research Shows

The short answer is: probably yes, modestly, and with more confidence about safety than about size of benefit. Two recent meta-analyses show the range of how the same body of evidence can be read.

A 2025 systematic review and meta-analysis in Biological Psychiatry Global Open Science covered 56 articles and 1,709 patients with bipolar depression. In sham-controlled randomized trials, active TMS beat sham with an effect size of Cohen's d = 0.40, which is a small-to-moderate difference. When the active arms of those trials were pooled with uncontrolled studies, the response rate was about 47 percent and the remission rate about 28 percent, similar to figures reported for major depressive disorder. Higher baseline illness severity and a greater number of sessions predicted a larger benefit. Both high-frequency left DLPFC protocols (including iTBS) and low-frequency right DLPFC protocols were associated with positive outcomes. The authors concluded that TMS is efficacious and safe in bipolar depression.

A 2026 meta-analysis in the Canadian Journal of Psychiatry took a stricter view, limiting itself to sham-controlled randomized trials: 17 trials, 563 participants, with a mean treatment duration of only about 2.4 weeks. It found a small benefit over sham (SMD = -0.34), with a response risk ratio of 1.41 and a remission risk ratio of 1.54. However, 15 of the comparisons (88.2%) did not show a significant advantage for TMS over sham at the individual-trial level, and the pooled effect was not consistently confirmed in sensitivity analyses. The authors judged the current evidence insufficient to call TMS an efficacious treatment at the doses tested and called for larger trials with higher-dose protocols. Their analysis also found that more total pulses was associated with a greater reduction in depressive symptoms.

Reading the two together: the published trials are small and short, the average effect is modest, and individual trials often miss statistical significance. At the same time, the direction of the effect is consistently in favor of TMS and nothing in either review points to a safety signal. That is the realistic picture to bring to a conversation with a psychiatrist, rather than either "proven" or "unproven".

Mood Switching and Safety

On the critical question of mood switching, the 2025 meta-analysis found that treatment-emergent mania or hypomania occurred at low rates and was statistically indistinguishable from sham (odds ratio 1.3; 95% confidence interval 0.7 to 2.4). The confidence interval is wide, so the data cannot rule out a small difference, which is why clinical monitoring remains standard. Clinicians generally keep mood-stabilizing medications in place during the treatment course.

The 2026 Canadian review reported no seizures and no serious adverse events among the randomized trials, and adverse events did not differ from sham. Across the larger 2025 pooled sample, the most common adverse effects were mild and transient, primarily scalp discomfort and headache, with one isolated uncomplicated seizure reported among 1,709 patients - consistent with the very rare seizure risk associated with TMS generally.

TMS for Bipolar II Depression

Bipolar II disorder is defined by depressive episodes alternating with hypomania rather than full mania, and depression makes up most of the time ill. People with bipolar II are well represented in the research: among the trials in the 2026 Canadian review that reported subtype, about 58 percent of participants had bipolar II and about 42 percent had bipolar I. The 2025 review noted that detailed subtype characterization was often missing from earlier studies, so firm subgroup-specific conclusions are not yet possible. In practice, bipolar II is not an exclusion for TMS, and the evaluation looks at the same things as for bipolar I: current mood state, cycling history and medications.

Who Makes a Good Candidate

A careful evaluation is meant to determine which patients are most likely to benefit from TMS for bipolar depression and to ensure the clinical context is right before treatment begins. Broadly, patients who tend to be strong candidates include those who:

  • Are experiencing an active depressive episode in the context of bipolar I or bipolar II disorder
  • Have tried at least one or two evidence-based medication approaches for bipolar depression without adequate relief, or have had to discontinue due to intolerable side effects
  • Are in a relatively stable mood state - not in active mania, not in a severe agitated mixed episode, and not in a psychiatric crisis requiring inpatient stabilization first
  • Do not have metallic implants in or near the head, such as cochlear implants, aneurysm clips, or deep brain stimulators - these are standard TMS contraindications that apply regardless of diagnosis
  • Can commit to attending five sessions per week for four to six weeks, which requires real scheduling planning for working adults and those with family responsibilities
  • Want to address depressive symptoms without adding a new oral antidepressant, or are interested in reducing overall medication burden over time under psychiatric supervision

Patients with rapid cycling bipolar disorder - defined as four or more distinct mood episodes per year - represent a more complex clinical picture. The evaluation pays additional attention to the current phase, recent cycling frequency, and what has preceded prior episodes. Rapid cycling is not an automatic exclusion from TMS, but it informs the approach and calls for more intensive monitoring during the treatment course.

Bipolar I patients with a strong history of severe manic episodes are evaluated more carefully, with attention to whether a robust antimanic mood stabilizer is firmly in place before TMS begins. A good provider takes an individualized approach seriously and does not apply generic eligibility criteria when a nuanced assessment is warranted. The guide on how to choose a TMS provider lists questions worth asking about bipolar experience.

What a TMS Course Usually Looks Like

Before TMS begins, every patient completes a thorough psychiatric evaluation. For patients with bipolar disorder, this covers the specific diagnosis and subtype, current mood state, history of prior episodes and any hospitalizations, medications currently prescribed and how well they are working, any substance use that could affect mood stability, and relevant medical and neurological history. A contraindication screening for metallic implants and other factors is also part of this evaluation.

TMS is most appropriate when a patient is in a depressive episode but not in acute crisis, and when mood has been stable enough that beginning a weeks-long outpatient course is realistic. If a patient presents in active mania or a severe mixed state, the clinical priority is first to stabilize mood - typically through medication adjustment - and then to revisit TMS once the acute phase has resolved and depression remains the dominant challenge.

Once a patient is deemed appropriate, the treatment structure is straightforward:

  • Five sessions per week, scheduled at times that work with the patient's professional and family life
  • Individual sessions run between six and forty minutes depending on whether theta burst or standard rTMS protocol is used
  • A full course typically involves twenty to thirty-six sessions delivered over four to six weeks
  • No sedation, no fasting, and no preparation of any kind is required before each session
  • Patients drive themselves to and from appointments and return to all normal activities the same day

During each session, the patient sits in a reclined treatment chair while a magnetic coil is positioned precisely over the target area of the scalp. A consistent positioning system ensures the coil lands in the same location at every session. Patients feel a tapping or clicking sensation on the scalp during the pulses. The most common side effect is mild scalp discomfort or a temporary headache, most noticeable during the first week and usually diminishing as treatment continues. There are no memory effects, no confusion afterward, and no impairment of cognitive function - a meaningful distinction from electroconvulsive therapy, which is another biological option sometimes considered in severe bipolar depression but carries genuine cognitive side effects that many patients find disqualifying.

For bipolar patients specifically, the clinical team should conduct brief structured check-ins throughout the treatment course to monitor not only for improvement in depressive symptoms but also for any early indicators of mood elevation - changes in sleep need, increases in energy or rate of speech, racing thoughts, or heightened irritability. If any concerning signs emerge, the protocol is adjusted or treatment is paused, with the patient's psychiatrist consulted before proceeding. This proactive monitoring is a standard part of responsible TMS care for anyone with a bipolar diagnosis, not an exceptional measure.

TMS and Your Existing Bipolar Medications

Patients frequently ask whether they need to stop their current medications to do TMS. For mood stabilizers, the answer is clearly no - and stopping lithium, valproate, or lamotrigine to pursue TMS is strongly discouraged. These medications should be continued throughout the entire TMS course. Stopping them abruptly would introduce unnecessary mood instability and could undermine both the safety and the effectiveness of treatment.

TMS does not interact pharmacologically with any of these drugs. The magnetic pulses act on brain tissue locally and do not affect how the body absorbs, distributes, metabolizes, or eliminates any medication. Lithium blood levels are not affected. Anticonvulsant concentrations remain stable. Antipsychotic plasma levels are unchanged. From a purely pharmacological standpoint, there is no conflict between TMS and any standard bipolar medication regimen.

There are a small number of considerations worth reviewing during the pre-treatment intake. Medications that significantly lower the seizure threshold warrant attention, since TMS carries a very small seizure risk. Some data also suggests that high-dose benzodiazepines may modestly blunt the cortical excitability that TMS aims to promote, though this is typically not a reason to change medications before beginning treatment. The clinician should review your full medication list - including over-the-counter drugs and supplements - during the intake process and flag anything that warrants a specific conversation.

In some cases, a successful TMS course opens the door to eventually optimizing the medication regimen - for example, working with a psychiatrist to reduce the dose of a partially effective drug that has been causing side effects, once mood stability has been consolidated. This is never a guaranteed outcome of TMS, and any medication adjustments should happen under careful psychiatric supervision over time. Medication reduction should not be expected as a routine result.

TMS Compared to ECT and Ketamine for Bipolar Depression

Understanding where TMS fits relative to other biological treatment options helps patients and families make informed decisions. The main alternatives for bipolar depression that has not responded to standard medications are electroconvulsive therapy (ECT) and ketamine or esketamine treatment.

ECT remains the most powerful acute biological treatment for severe depression, including bipolar depression. It is delivered in a hospital or outpatient surgical setting, requires general anesthesia, and produces a brief controlled seizure. Its speed of action is genuinely useful in the most severe situations - particularly when suicide risk is high, when the patient cannot care for themselves, or when a rapid response is medically necessary. Its limitations include the requirement for anesthesia and escort care after each session, and memory side effects that, while often temporary, are a real concern for many patients and can occasionally persist. For patients with the most urgent and severe presentations, ECT may be the more appropriate recommendation, and a responsible clinician will say so directly rather than steering you toward TMS when a different treatment is more likely to help.

Ketamine infusions and esketamine nasal spray (Spravato) have demonstrated rapid antidepressant effects, sometimes within hours of administration, and emerging research is examining their application in bipolar depression specifically. The main limitations are that effects can be short-lived and may require ongoing infusions or doses to sustain, cost and availability vary considerably, and there are open questions about long-term ketamine use in bipolar patients given the potential to affect mood cycling. Some clinicians use ketamine and TMS in a complementary sequence. This combination approach is individualized and requires careful clinical judgment rather than being a standard protocol. A fuller comparison is in the guide to TMS therapy versus ketamine infusions.

TMS occupies a practical middle ground in this landscape. It is not as fast-acting as ketamine and not as powerful in the most severe acute presentations as ECT. But it is non-invasive, requires no anesthesia, produces no cognitive side effects, and fits into a working life without major disruption. For patients with moderate bipolar depression that has not responded adequately to medications but who are not in acute crisis, TMS is often a reasonable next step to explore, bearing in mind the modest effect sizes described above.

Insurance, Cost, and Coverage in Boca Raton

Because TMS for bipolar depression is currently off-label for most TMS devices, insurance coverage is less predictable than for TMS used for FDA-cleared major depressive disorder. It is worth asking about openly before treatment, because patients deserve accurate information before making any financial commitment.

That said, off-label coverage does occur in Florida. Some commercial insurers have approved TMS for bipolar depression when prior authorization documentation clearly establishes medical necessity - including a confirmed bipolar diagnosis, a documented record of prior medication trials that failed or were not tolerated, and a detailed clinical rationale from the treating psychiatrist. Coverage determinations are plan-specific and change over time, so verifying current policy directly with your insurer is essential rather than relying on historical patterns or general statements.

Medicare covers TMS for major depressive disorder but does not have a national coverage determination specifically extending to bipolar depression as of this writing. Verify the current Medicare coverage determination at medicare.gov or by asking the clinic's billing staff, as federal coverage policies continue to evolve. Medicaid coverage in Florida for off-label TMS is rare.

For patients paying out of pocket, a full TMS course represents a significant financial investment that varies based on protocol and session count. Ask the provider for clear, upfront pricing during the intake process and for any payment options. It is also worth asking whether the clinic's billing staff assist with prior authorization submissions, documentation of clinical rationale, and the appeals process when an initial denial comes back. Appeals supported by thorough clinical documentation and published evidence sometimes succeed.

Life After TMS: Maintaining Gains in Bipolar Disorder

Bipolar disorder is a lifelong condition, and thinking about what comes after an initial TMS course is just as important as the treatment itself. Patients who respond well to TMS typically experience an extended period of meaningfully improved mood - often lasting several months, and for some patients considerably longer - particularly when TMS is integrated with stable medication management, ongoing psychiatric care, and lifestyle practices that support mood stability.

When depressive symptoms begin to return after a successful course, maintenance or booster TMS is a meaningful option. A booster series is typically shorter than the initial course - often five to fifteen sessions - and is most effective when initiated early, at the first sign of returning depressive symptoms, rather than waiting until a full episode has consolidated. The guide to TMS maintenance and booster sessions explains how this usually works.

Boca Raton and broader Palm Beach County offer solid resources for ongoing mental health support - outpatient psychiatric practices, licensed therapists experienced in bipolar disorder, and psychoeducation programs that help patients and families recognize early warning signs of episode recurrence. Lifestyle factors that consistently support better long-term outcomes in bipolar disorder include maintaining a regular sleep schedule (sleep disruption is one of the most reliable triggers for mood episodes), regular aerobic exercise, limiting or eliminating alcohol and cannabis use (both destabilize mood cycling and interfere with medication effectiveness; see the guide to dual diagnosis, where mental health and substance use overlap), active stress management, and sustained therapeutic relationships. TMS works best as part of this comprehensive picture rather than as a standalone replacement for it.

Frequently Asked Questions

Is TMS FDA-approved specifically for bipolar depression?

TMS received FDA clearance for major depressive disorder in 2008, and that remains the primary cleared indication for most TMS devices. For most available systems, bipolar depression is currently an off-label application in the United States. The 2025 review in Biological Psychiatry Global Open Science notes that rTMS has received FDA breakthrough status for bipolar depression, which is not the same as clearance. Regulatory status can change, so verify the current picture at fda.gov or with the treating clinician.

Does TMS work for bipolar disorder?

It appears to help the depressive phase modestly. A 2025 meta-analysis reported an effect size of 0.40 against sham, with response around 47 percent and remission around 28 percent in pooled active arms. A stricter 2026 analysis of sham-controlled trials found a smaller effect (SMD -0.34) and noted that most individual trials were not significant. TMS is not used for mania.

Will TMS trigger a manic episode or hypomania in bipolar patients?

This is the most understandable concern for anyone with a bipolar diagnosis. The 2025 meta-analysis found treatment-emergent mania or hypomania at low rates, not different from sham (odds ratio 1.3; 95% confidence interval 0.7 to 2.4). Because the interval is wide, clinicians still monitor sleep, energy and mood throughout the course and adjust or pause treatment if elevation appears.

Is TMS effective for bipolar 2?

People with bipolar II make up a majority (about 58 percent) of participants in the 2026 Canadian review among trials that reported subtype, so the evidence is not limited to bipolar I. Subgroup-specific conclusions are still limited because subtype data were often not reported. Bipolar II is not by itself a reason to be excluded from TMS.

Do I have to stop my lithium or other bipolar medications to do TMS?

In almost every case, no - and stopping mood stabilizers before or during TMS is strongly discouraged. Lithium, valproate, lamotrigine, and atypical antipsychotics used for mood stabilization can all be continued throughout a TMS course without pharmacological conflict. TMS does not affect blood levels or the metabolism of any of these medications. If any specific drugs in your regimen require discussion before treatment begins, the clinician should identify them during the intake evaluation.

How many sessions will I need, and can I keep working during treatment?

A standard TMS course involves five sessions per week for four to six weeks, totaling between twenty and thirty-six sessions. With theta burst stimulation, individual sessions can be as short as six minutes; standard rTMS sessions run twenty to forty minutes. Because no sedation is involved and there is no recovery time, most patients schedule sessions before work, at lunch, or after work and resume all normal activities immediately afterward.

What if my insurance denies coverage for bipolar depression TMS?

When an initial claim is denied, ask the provider whether the clinic supports the formal appeals process. Thorough documentation of medical necessity, drawing on your diagnostic history, documented prior treatment trials, and published clinical evidence, sometimes succeeds on appeal. If coverage remains unavailable, ask for transparent out-of-pocket cost information and payment options, and ask the clinician whether a different treatment approach might be more appropriate for your situation.

How does TMS for bipolar depression compare to ECT?

ECT is the more powerful biological treatment and is appropriate when bipolar depression is severe, urgent, or accompanied by high suicide risk. It requires general anesthesia and carries real memory side effects. TMS is non-invasive, requires no anesthesia, produces no cognitive side effects, and integrates into a working outpatient life. For patients in severe or urgent crisis, ECT may genuinely be the better recommendation, and a responsible clinician will tell you so based on your individual picture.

If the depressive phases of your bipolar disorder are not responding adequately to your current treatment plan, TMS may be a meaningful next step worth discussing with your psychiatrist or another qualified clinician. Questions worth bringing to a first appointment include how the provider monitors for mood elevation, how TMS fits with your current medications, and what coverage to expect. For related reading, see the guides to TMS side effects and safety and TMS cost and insurance coverage.

Keep reading

This guide offers general information, not medical advice. Always talk to a licensed professional about your own situation.

Read the TMS guide